



**WE CLAIM:**

1. A compound of Formula (I),



and anhydrate or hydrate forms thereof, wherein R<sub>1</sub> is Cl or Br; X is CH, N, or CF; and Het is thiazole or furan.

2. A compound of Formula (II),



and anhydrate or hydrate forms thereof.

3. The compound as claimed in claim 2, wherein the compound is the anhydrate form.

4. The compound as claimed in claim 2, wherein the compound is characterized by a powder x-ray diffraction pattern, comprising the peaks:


Two theta (deg)	d-spacing (angstroms)
4.8	18
8.7	10
18.0	4.9
18.9	4.7
21.0	4.2
22.3	4.0

5. The compound as claimed in claim 2, wherein the compound is the monohydrate form.

6. The compound as claimed in claim 2, wherein the compound is characterized by a powder x-ray diffraction pattern, comprising the peaks:

Two theta (deg)	d-spacing (angstroms)
6.6	13
8.3	10
11.5	7.7
18.1	4.9
21.1	4.2

7. The compound as claimed in claim 1, wherein the compound is a compound of




Formula (III)

(III)

and anhydrate or hydrate forms thereof.

8. The compound as claimed in claim 1, wherein the compound is a compound of Formula (IV)



(IV)

and anhydrate or hydrate forms thereof.

9. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound, or anhydrate or hydrate forms thereof, as claimed in any of claims 1 to 8 and one or more of pharmaceutically acceptable carriers, diluents and excipients.
10. A pharmaceutical composition as claimed in claim 9, capable of being used in the manufacture of a medicament for the treatment of a disorder in a mammal, said disorder being characterized by aberrant activity of at least one erbB family PTK.
11. A pharmaceutical composition as claimed in claim 10, wherein said erbB family PTK is selected from the group consisting of EGFr, c-erb-B2, and c-erb-B4.
12. A pharmaceutical composition as claimed in claim 10, wherein at least two erbB family PTKs selected from the group consisting of EGFr, c-erb-B2, and c-erb-B4 exhibit aberrant activity.

13. A pharmaceutical composition as claimed in claim 10, wherein at least one erbB family PTK selected from the group consisting of EGFr, c-erb-B2, and c-erb-B4 is inhibited by the compound.
14. A pharmaceutical composition as claimed in claim 10, wherein at least two erbB family PTKs selected from the group consisting of EGFr, c-erb-B2, and c-erb-B4 are inhibited by the pharmaceutical composition.
15. The pharmaceutical composition as claimed in claim 10, wherein the disorder is cancer or psoriasis.
16. The pharmaceutical composition as claimed in claim 10, wherein the disorder is cancer.